… reduced the rates of moderate/severe COPD exacerbations and improved lung … than
budesonide/formoterol and/or glycopyrronium/formoterol. Budesonide/glycopyrronium/formoterol …

… 1.87 exacerbations per patient per year in the budesonide/formoterol, budesonide, formoterol
and placebo treatment groups, respectively. Budesonide/formoterol significantly reduced …

… were identified in this study compared with what is previously known for budesonide/formoterol,
budesonide and formoterol in COPD and asthma. The mean number of AEs …

… The primary objective of this study was to assess the onset of action of formoterol/budesonide
compared with that of formoterol. The primary variable for this comparison was therefore …

… of the time to first COPD exacerbation and reduction in … with budesonide/formoterol pMDI
compared with formoterol treatment… with budesonide/formoterol pMDI compared with formoterol. …

… patients in both budesonide/formoterol pMDI treatment groups compared with patients in the
budesonide, formoterol … in patients with COPD treated with budesonide/formoterol DPI 320/…

… Although the use of antibiotics was not part of the definition of exacerbation in the present
study, the use of antibiotics for worsening of COPD was lower in the budesonide/formoterol …

… rate of COPD exacerbations and … budesonide/formoterol versus formoterol and placebo.
Moreover, the time to first exacerbation was significantly prolonged with budesonide/formoterol …

… only so far reported study with budesonide/formoterol in COPD patients and acute …
patients with baseline mean FEV 1 values around 0.85 L. The patients in our study were out-patients …

… COPD patients receiving budesonide/formoterol was greater than that seen with formoterol
alone and the proportion of patients … the budesonide/formoterol versus the formoterol group. …